Guangzhou Huajin Pharmaceutical Technology Co., Ltd.-News

The oncolytic bacteria drug SalMet-Vec® has obtained the Orphan Drug Designation (ODD) from FDA for the treatment of pancreatic cancer

넶6 2025-01-08
Sinogen Pharmaceutical has been selected as a "Future Unicorn" innovative enterprise in Guangzhou for 3 consecutive years

넶25 2024-12-30
Sinogen Pharmaceutical was elected as one of the "Top Ten Enterprises" in the 13th China Innovation and Entrepreneurship Competition (Guangdong Guangzhou Division)

넶64 2024-11-08
Sinogen Pharmaceutical's investigational new drug has been selected for the service list of key drug varieties in the Greater Bay Area

넶202 2024-07-11
Cell Death and Disease (IF:9.0) published oncological bacterium SalMet-Vac ® research paper on the treatment of osteosarcoma

넶137 2024-05-29

Position：Home > News

Press Releases
Industry Dynamics

Press Releases

——

Address：Room 101, 1st Floor, Building C5, Science and Technology Enterprise Accelerator, Huangpu District, Guangzhou Email : sinogen@sinogen.cc Service Time : Work days 9:00 ~ 17:00

About Us

Science&Prouduct

News

Contact Us

sinogen@sinogen.cc
Work days 9: 00 ~17: 00
Address：Room 101, 1st Floor, Building C5,
Science and Technology Enterprise Accelerator,
Huangpu District, Guangzhou

Investor Relations

Shareholder Information

Careers

The oncolytic bacteria drug SalMet-Vec® has obtained the Orphan Drug Designation (ODD) from FDA for the treatment of pancreatic cancer

Sinogen Pharmaceutical has been selected as a "Future Unicorn" innovative enterprise in Guangzhou for 3 consecutive years

Sinogen Pharmaceutical was elected as one of the "Top Ten Enterprises" in the 13th China Innovation and Entrepreneurship Competition (Guangdong Guangzhou Division)

Sinogen Pharmaceutical's investigational new drug has been selected for the service list of key drug varieties in the Greater Bay Area

Cell Death and Disease (IF:9.0) published oncological bacterium SalMet-Vac ® research paper on the treatment of osteosarcoma